JENA, Germany, Sept. 12, 2025 – InflaRx N.V. (Nasdaq: IFRX), a company focused on anti-inflammatory therapeutics by targeting the complement system, announced today that it has received notification from Nasdaq, dated September 11, 2025, stating that it has met the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).
The notification confirms that InflaRx is compliant because its ordinary shares’ closing bid price was $1.00 or greater for 10 consecutive business days, from August 27, 2025, to September 10, 2025, resolving the issue.
About InflaRx N.V.
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing its anti-C5a and anti-C5a receptor technologies to discover, develop, and commercialize potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a key inflammatory mediator in various inflammatory diseases. InflaRx’s lead product, vilobelimab, is a novel, intravenously administered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has shown disease-modifying clinical activity and tolerability in clinical studies. The company is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.
Founded in 2007, InflaRx has offices and subsidiaries in Jena and Munich, Germany, and Ann Arbor, MI, USA. More information is available at www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (collectively, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: |
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements, identifiable by terms like “may,” “will,” “should,” and others. These statements, found throughout the release, concern intentions, beliefs, projections, and expectations, and involve risks, uncertainties, and other factors detailed in the company’s SEC filings under “Risk factors” and “Cautionary statement regarding forward looking statements.” These factors could cause actual results to differ materially from those expressed or implied. Therefore, undue reliance should not be placed on these statements, and the company undertakes no obligation to update them, even with new information, except as legally required.
“`